Experts RQM+ Bring IVDR Thematic Search Tool Free to Market to Help Increase Compliance Efficiency

Every day, regulatory, clinical, quality, and marketing teams at diagnostics manufacturers must refer to the EU’s upcoming In Vitro Diagnostic Regulation (IVDR). In order to make this process easier, a new, freely available IVDR filtering tool is being offered to the market by RQM+, the world’s leading medical device and diagnostics focused regulatory and quality consulting firm.

The tool has organized the IVDR by key themes and allows users to navigate the legislation using the subject areas most likely to be relevant to their day-to-day work.

Even though the MDR deadline was delayed to May 2021, the impending deadlines for the IVDR have not yet changed, so diagnostics companies remain under considerable time pressure to achieve compliance with the new Regulation to keep their products available on the EU marketplaces. Failure to comply on time could result in CE mark certification being withdrawn. Therefore, any ways to make regulatory preparation more efficient will benefit the whole diagnostics industry to participate effectively in EU markets.

Legislation is drafted to define legal responsibilities, rather than to provide optimum ‘searchability’ for Regulatory, Clinical, and Quality Assurance professionals. RQM+ has drawn on its wide-ranging and in-depth expertise to overlay IVDR with thematic metadata which categorises each section by fundamental compliance themes. Using this tool, regulatory, clinical, and quality teams can save considerable amounts of administrative time and concentrate their precious expert effort on professional workflows.

Providing this tool free, for the general benefit of the diagnostics industry, is the initiative of Nancy Morrison, RQM+ Executive Director, Regulatory & Quality Consulting Services. She notes, “There’s nothing more frustrating than to have to spend time searching through legislation to gather the key sections (or even sentences!) for each phase of regulatory compliance. That’s something I’ve even been told by regulators and notified bodies! Many colleagues across the sector have already been using our IVDR search tool, and we look forward to adding its MDR equivalent soon. In this way, our initiative can become even more worthwhile.”

The RQM+ IVDR Search Tool is available to download here.

The company is hosting a webinar. Details here.

SourceRQM+

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”